Showing 61 - 70 of 273
The nation's spending for prescription drugs has grown dramatically in recent years. Previous studies have shown that the replacement of older drugs by newer, more expensive, drugs is the single most important reason for this increase, but they did not measure how much of the difference between...
Persistent link: https://www.econbiz.de/10011397709
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% G from 69.7 to 76.5 years G and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase, there...
Persistent link: https://www.econbiz.de/10011397757
Persistent link: https://www.econbiz.de/10011428372
Persistent link: https://www.econbiz.de/10009701622
Persistent link: https://www.econbiz.de/10009657491
Persistent link: https://www.econbiz.de/10009616652
Persistent link: https://www.econbiz.de/10009714421
There were no innovations in chemotherapy for myeloma patients during the period 1977-1997, but there have been several important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma patients using both time-series U.S. data and...
Persistent link: https://www.econbiz.de/10010223067
Persistent link: https://www.econbiz.de/10010386634
I analyze the effects of four types of medical innovation and cancer incidence on US cancer mortality rates during the period 2000–2009, by estimating difference-in-differences models using longitudinal (annual) data on ∼60 cancer sites (breast, colon, etc.). The outcome measure used is not...
Persistent link: https://www.econbiz.de/10010466909